Investigating Brain, Mood, and Appetite Changes After Stopping GLP-1 Agonist Tirzepatide
Background
GLP-1 (Glucagon-like Peptide-1) receptor agonists like Tirzepatide are highly effective for weight loss and managing type 2 diabetes, significantly improving metabolic health and appetite regulation. While their benefits are well-documented, the neurobehavioral and physiological consequences of discontinuing these powerful drugs, particularly on brain activity, mood, and eating behaviors, remain largely unexplored. This study aims to fill this critical knowledge gap by examining the precise impact of temporarily pausing and then reinitiating Tirzepatide on various clinical and neurobehavioral parameters.
Study Design
Results
As this is a 'NOT_YET_RECRUITING' study, specific findings are not yet available. However, the study is meticulously designed to uncover the precise clinical and neurobehavioral changes associated with Tirzepatide discontinuation and reinitiation in its 40 estimated participants. Researchers anticipate observing measurable alterations in brain activity patterns, particularly in regions associated with reward and appetite regulation, during the 3-4 week discontinuation phase. They will quantify changes in appetite, food cravings, and mood states, expecting to see a return towards baseline or even an exacerbation of pre-treatment symptoms in some individuals. > The primary objective is to precisely characterize the physiological and psychological rebound effects when Tirzepatide is temporarily stopped, providing quantitative data on changes in brain function, eating behavior, and mood. The study will also analyze gut microbiome (the community of microorganisms living in the digestive tract) composition from stool samples, aiming to correlate any observed shifts with neurobehavioral changes, potentially revealing novel gut-brain axis interactions.
Why It Matters
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to pause or discontinue Tirzepatide for various reasons, and knowing the neurobehavioral consequences will allow clinicians to better prepare and support them through these transitions. This research could provide valuable insights into the mechanisms underlying Tirzepatide's effects on the brain and behavior, extending beyond simple weight loss. Ultimately, the findings could lead to improved clinical guidelines for managing GLP-1 agonist therapy, potentially influencing how these powerful drugs are prescribed and discontinued in the future. The study is planned to start in June 2026 and complete in February 2029, with results expected thereafter.